Expert Interview
A second view: Digging into the Phase 1 data on Affimed's AFM24 and atezolizumab combination in patients with EGFR+ solid tumors
Ticker(s): AFMDInstitution: Hospital Fundacion Jimenez Diaz, Madrid (START Madrid)
- Director of Clinical Research at the Phase 1 Trials Unit START Madrid-FJD.
- Treats over 250 patients per year with solid tumors.
- Primary investigator on more than 30 phase 1 clinical trials in Medical oncology, Neuro-Oncology and Gastrointestinal Tumors; Research expertise in early clinical trials and drug development with special focus on targeted therapies, cancer immunotherapy and adoptive cell therapy.
What percent of your patients could benefit from upcoming novel drugs? How much need is there for a tetravalent, bispecific innate cell engager such as AFM24?
Added By: max_adminCould you the mechanism of action behind the drug’s ability to bind to CD16A on innate immune cells and EGFR, and how that translates into better patient outcomes? Where do you see the benefits of this approach vs standard care?
Added By: max_adminHow likely is it for AFM24 + Atezolizumab 1PR (Gastric) or 1SD (Pancreatic) to become the preferred method of treatment, based on the recent data?
Added By: max_adminThe company has stated in the past that every patient overexpressing EGFR could be eligible for treatment with AFMD24 irrespective of mutational status. How would you assess that statement?
Added By: max_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
